Share Price and Basic Stock Data
Last Updated: December 19, 2025, 6:33 pm
| PEG Ratio | 1.75 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Everest Organics Ltd operates in the pharmaceuticals sector, a field characterized by its volatility and competition. As of the latest reports, the company’s stock price stood at ₹458, reflecting a market capitalization of ₹445 Cr. The company’s revenue trends have shown fluctuation, with sales for the fiscal year ending March 2023 recording ₹183 Cr, a decline from ₹200 Cr in FY 2022. However, the trailing twelve-month (TTM) sales have shown some resilience, reported at ₹181 Cr. Notably, quarterly sales have varied significantly, with a peak of ₹52.62 Cr in March 2024 before dipping to ₹32.45 Cr in June 2024. This inconsistency in revenue generation raises questions about the company’s ability to maintain steady growth amidst market challenges.
Profitability and Efficiency Metrics
Profitability metrics for Everest Organics reveal a mixed picture. The net profit for the year ending March 2023 was a meager ₹0.11 Cr, down from ₹1 Cr in the previous fiscal year. This led to a net profit margin of -0.09% for FY 2023, indicating the company struggled to convert sales into actual profit. The operating profit margin (OPM) stood at 5% for FY 2025, which appears weak when compared to industry norms. Additionally, the company’s return on equity (ROE) and return on capital employed (ROCE) were reported at 2.23% and 1.76%, respectively, suggesting that the company is not generating sufficient returns on its equity and capital investment. With a cash conversion cycle of 17 days, Everest seems to manage its working capital reasonably well, but the overall profitability metrics indicate a need for improvement.
Balance Sheet Strength and Financial Ratios
The balance sheet of Everest Organics presents a cautious picture. The company holds reserves of ₹60 Cr against borrowings of ₹48 Cr, which looks comfortable in terms of leverage. The interest coverage ratio (ICR) is at 1.52x, which suggests that while the company can cover its interest obligations, it is operating close to a tight margin. The price-to-book value (P/BV) ratio of 3.50x indicates that the stock might be overvalued relative to its book value of ₹72.03 per share. Moreover, the total debt-to-equity ratio of 0.68x reflects a manageable debt level but raises concerns regarding the sustainability of growth in a capital-intensive industry. Overall, while the balance sheet isn’t under severe strain, the financial ratios hint at a cautious approach needed for future financial stability.
Shareholding Pattern and Investor Confidence
Investor confidence in Everest Organics appears to be waning, as evidenced by the shifting shareholding pattern. Promoter holding has decreased from 74.15% in early 2023 to 59.64% by September 2025, indicating potential concerns among insiders about the company’s future performance. The public shareholding has increased from 25.83% to 40.35% during the same period, suggesting that retail investors are stepping in, possibly at attractive valuations. However, the presence of foreign institutional investors (FIIs) remains absent, which could be a red flag for institutional faith in the company. The number of shareholders has also declined from 11,100 in December 2022 to 8,079 in September 2025, reflecting a potential exit of investors who may be dissatisfied with the company’s performance.
Outlook, Risks, and Final Insight
Looking ahead, Everest Organics faces a series of challenges and opportunities. The fluctuating sales and profitability metrics suggest that the company needs to refine its operational efficiencies to achieve sustainable growth. Risks include the potential for continued revenue volatility and reliance on a narrow product portfolio, which could hinder growth in a competitive market. Additionally, the decline in promoter holdings could signify a lack of confidence among key stakeholders. However, the increase in public shareholding may also reflect a view that the stock is undervalued at current levels. Investors should remain cautious, keeping an eye on operational improvements and market conditions. A prudent approach would be to monitor how the company addresses its profitability issues and whether it can stabilize its revenue streams in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.63 Cr | 1,151.17 | 52.65 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.03 | 45.97 | 43.29 | 50.75 | 42.67 | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 |
| Expenses | 44.67 | 43.20 | 45.79 | 48.47 | 40.15 | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 |
| Operating Profit | -1.64 | 2.77 | -2.50 | 2.28 | 2.52 | 2.71 | 2.80 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 |
| OPM % | -3.81% | 6.03% | -5.78% | 4.49% | 5.91% | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.40% | 8.25% |
| Other Income | 0.39 | 0.22 | 5.65 | 0.69 | 0.22 | 0.24 | 0.13 | 0.30 | 0.33 | 0.14 | 0.00 | 0.22 | 0.55 |
| Interest | 0.69 | 0.85 | 0.81 | 0.95 | 1.29 | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.40 | 1.15 | 1.31 |
| Depreciation | 0.99 | 1.13 | 1.10 | 1.26 | 1.29 | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 |
| Profit before tax | -2.93 | 1.01 | 1.24 | 0.76 | 0.16 | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 |
| Tax % | -5.80% | 6.93% | -21.77% | 85.53% | 75.00% | 78.57% | 93.33% | 62.50% | 0.00% | 0.00% | 0.87% | -206.32% | 35.19% |
| Net Profit | -2.75 | 0.94 | 1.52 | 0.11 | 0.04 | 0.03 | 0.02 | 0.06 | -6.09 | 0.75 | 1.14 | 2.91 | 1.41 |
| EPS in Rs | -3.44 | 1.18 | 1.90 | 0.14 | 0.05 | 0.04 | 0.02 | 0.08 | -7.61 | 0.94 | 1.42 | 3.00 | 1.45 |
Last Updated: August 19, 2025, 3:46 pm
Below is a detailed analysis of the quarterly data for Everest Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 53.81 Cr.. The value appears strong and on an upward trend. It has increased from 40.93 Cr. (Mar 2025) to 53.81 Cr., marking an increase of 12.88 Cr..
- For Expenses, as of Jun 2025, the value is 49.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37.49 Cr. (Mar 2025) to 49.37 Cr., marking an increase of 11.88 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.44 Cr.. The value appears strong and on an upward trend. It has increased from 3.44 Cr. (Mar 2025) to 4.44 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 8.25%. The value appears to be declining and may need further review. It has decreased from 8.40% (Mar 2025) to 8.25%, marking a decrease of 0.15%.
- For Other Income, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 1.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.15 Cr. (Mar 2025) to 1.31 Cr., marking an increase of 0.16 Cr..
- For Depreciation, as of Jun 2025, the value is 1.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.56 Cr. (Mar 2025) to 1.52 Cr., marking a decrease of 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.95 Cr. (Mar 2025) to 2.16 Cr., marking an increase of 1.21 Cr..
- For Tax %, as of Jun 2025, the value is 35.19%. The value appears to be increasing, which may not be favorable. It has increased from -206.32% (Mar 2025) to 35.19%, marking an increase of 241.51%.
- For Net Profit, as of Jun 2025, the value is 1.41 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 1.41 Cr., marking a decrease of 1.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 3.00 (Mar 2025) to 1.45, marking a decrease of 1.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 188 |
| Expenses | 91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 171 |
| Operating Profit | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 17 |
| OPM % | 6% | 7% | 6% | 6% | 6% | 11% | 12% | 13% | 3% | 1% | 6% | 5% | 9% |
| Other Income | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
| Depreciation | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
| Profit before tax | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 7 |
| Tax % | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | |
| Net Profit | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 7 |
| EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 7.06 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -100.00% | 100.00% | 300.00% | 37.50% | 27.27% | -92.86% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 200.00% | 200.00% | -262.50% | -10.23% | -120.13% | -7.14% |
Everest Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2014-2015 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -1% |
| 3 Years: | -7% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 204% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 44% |
| 1 Year: | 182% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| Last Year: | -2% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 |
| Reserves | -5 | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 | 63 |
| Borrowings | 26 | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | 49 |
| Other Liabilities | 35 | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 107 | 115 |
| Total Liabilities | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
| Fixed Assets | 24 | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 54 | 50 | 49 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 19 | 23 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 41 | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 152 | 166 |
| Total Assets | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
Below is a detailed analysis of the balance sheet data for Everest Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2025) to 63.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 48.00 Cr. (Mar 2025) to 49.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 115.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 107.00 Cr. (Mar 2025) to 115.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 237.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 224.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 166.00 Cr.. The value appears strong and on an upward trend. It has increased from 152.00 Cr. (Mar 2025) to 166.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 224.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 13.00 Cr..
Notably, the Reserves (63.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -16.00 | -22.00 | -13.00 | -15.00 | -3.00 | 1.00 | 0.00 | -33.00 | -50.00 | -47.00 | -41.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 |
| Inventory Days | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 |
| Days Payable | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 351 |
| Cash Conversion Cycle | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 17 |
| Working Capital Days | -43 | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -21 | 3 |
| ROCE % | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Diluted EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Cash EPS (Rs.) | 4.81 | 7.42 | 5.36 | 6.17 | 21.36 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.50 | 1.50 |
| Revenue From Operations / Share (Rs.) | 164.23 | 246.55 | 228.81 | 250.06 | 226.96 |
| PBDIT / Share (Rs.) | 8.14 | 14.84 | 9.84 | 10.80 | 29.88 |
| PBIT / Share (Rs.) | 2.00 | 7.60 | 4.25 | 6.05 | 25.66 |
| PBT / Share (Rs.) | -3.34 | 0.76 | 0.11 | 2.17 | 21.59 |
| Net Profit / Share (Rs.) | -1.33 | 0.17 | -0.22 | 1.43 | 17.14 |
| PBDIT Margin (%) | 4.95 | 6.01 | 4.30 | 4.31 | 13.16 |
| PBIT Margin (%) | 1.22 | 3.08 | 1.85 | 2.42 | 11.30 |
| PBT Margin (%) | -2.03 | 0.30 | 0.04 | 0.86 | 9.51 |
| Net Profit Margin (%) | -0.80 | 0.07 | -0.09 | 0.57 | 7.55 |
| Return on Networth / Equity (%) | -1.84 | 0.30 | -0.39 | 2.44 | 29.44 |
| Return on Capital Employeed (%) | 2.30 | 9.12 | 5.28 | 7.39 | 35.38 |
| Return On Assets (%) | -0.57 | 0.06 | -0.09 | 0.64 | 10.13 |
| Long Term Debt / Equity (X) | 0.13 | 0.31 | 0.25 | 0.23 | 0.12 |
| Total Debt / Equity (X) | 0.68 | 1.26 | 1.10 | 0.82 | 0.42 |
| Asset Turnover Ratio (%) | 0.70 | 0.92 | 0.96 | 1.28 | 1.42 |
| Current Ratio (X) | 1.06 | 0.93 | 0.96 | 1.05 | 1.15 |
| Quick Ratio (X) | 0.73 | 0.66 | 0.62 | 0.67 | 0.72 |
| Inventory Turnover Ratio (X) | 3.58 | 2.73 | 2.83 | 3.77 | 3.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | -219.53 | 69.94 | 8.74 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 9.32 | 16.19 | 7.02 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 319.53 | 30.06 | 91.26 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 90.68 | 83.81 | 92.98 |
| Interest Coverage Ratio (X) | 1.52 | 2.17 | 2.38 | 2.78 | 7.34 |
| Interest Coverage Ratio (Post Tax) (X) | 0.75 | 1.03 | 0.94 | 1.37 | 5.21 |
| Enterprise Value (Cr.) | 285.94 | 148.80 | 126.35 | 177.17 | 202.22 |
| EV / Net Operating Revenue (X) | 1.79 | 0.75 | 0.69 | 0.88 | 1.11 |
| EV / EBITDA (X) | 36.15 | 12.53 | 16.05 | 20.51 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| Retention Ratios (%) | 0.00 | 0.00 | 319.53 | 30.05 | 91.25 |
| Price / BV (X) | 3.50 | 2.00 | 1.65 | 2.97 | 3.95 |
| Price / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| EarningsYield | -0.01 | 0.00 | 0.00 | 0.01 | 0.07 |
After reviewing the key financial ratios for Everest Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.42 (Mar 24) to 4.81, marking a decrease of 2.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.23. It has decreased from 246.55 (Mar 24) to 164.23, marking a decrease of 82.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has decreased from 14.84 (Mar 24) to 8.14, marking a decrease of 6.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 7.60 (Mar 24) to 2.00, marking a decrease of 5.60.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.34. This value is below the healthy minimum of 0. It has decreased from 0.76 (Mar 24) to -3.34, marking a decrease of 4.10.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 2. It has decreased from 0.17 (Mar 24) to -1.33, marking a decrease of 1.50.
- For PBDIT Margin (%), as of Mar 25, the value is 4.95. This value is below the healthy minimum of 10. It has decreased from 6.01 (Mar 24) to 4.95, marking a decrease of 1.06.
- For PBIT Margin (%), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 1.22, marking a decrease of 1.86.
- For PBT Margin (%), as of Mar 25, the value is -2.03. This value is below the healthy minimum of 10. It has decreased from 0.30 (Mar 24) to -2.03, marking a decrease of 2.33.
- For Net Profit Margin (%), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to -0.80, marking a decrease of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.84. This value is below the healthy minimum of 15. It has decreased from 0.30 (Mar 24) to -1.84, marking a decrease of 2.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 10. It has decreased from 9.12 (Mar 24) to 2.30, marking a decrease of 6.82.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to -0.57, marking a decrease of 0.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.31 (Mar 24) to 0.13, marking a decrease of 0.18.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.68. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 0.68, marking a decrease of 0.58.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. It has decreased from 0.92 (Mar 24) to 0.70, marking a decrease of 0.22.
- For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has increased from 0.93 (Mar 24) to 1.06, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.73, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 3.58, marking an increase of 0.85.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 1.52, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 3. It has decreased from 1.03 (Mar 24) to 0.75, marking a decrease of 0.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 285.94. It has increased from 148.80 (Mar 24) to 285.94, marking an increase of 137.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.79, marking an increase of 1.04.
- For EV / EBITDA (X), as of Mar 25, the value is 36.15. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 36.15, marking an increase of 23.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 24) to 3.50, marking an increase of 1.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Everest Organics Ltd:
- Net Profit Margin: -0.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.3% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.84% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 66.3 (Industry average Stock P/E: 43.31)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.68
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Aroor Village, Sadasivpet Mandal, Sangareddy Dist. Telangana 502291 | e.cs@everestorganicsltd.com http://www.everestorganicsltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Prasad Venkata Satya Sundara Srikakolapu | Chairman & Ind.Director |
| Dr. Sri Kakarlapudi Sirisha | Managing Director |
| Mr. Srikakarlapudi Harikrishna | Whole Time Director |
| Mr. Kirankumar Rampally | Non Exe.Non Ind.Director |
| Mr. Venkata Satyanarayana Murthy Vadali | Independent Director |
FAQ
What is the intrinsic value of Everest Organics Ltd?
Everest Organics Ltd's intrinsic value (as of 19 December 2025) is 90.12 which is 80.06% lower the current market price of 452.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 439 Cr. market cap, FY2025-2026 high/low of 499/211, reserves of ₹63 Cr, and liabilities of 237 Cr.
What is the Market Cap of Everest Organics Ltd?
The Market Cap of Everest Organics Ltd is 439 Cr..
What is the current Stock Price of Everest Organics Ltd as on 19 December 2025?
The current stock price of Everest Organics Ltd as on 19 December 2025 is 452.
What is the High / Low of Everest Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Everest Organics Ltd stocks is 499/211.
What is the Stock P/E of Everest Organics Ltd?
The Stock P/E of Everest Organics Ltd is 66.3.
What is the Book Value of Everest Organics Ltd?
The Book Value of Everest Organics Ltd is 74.7.
What is the Dividend Yield of Everest Organics Ltd?
The Dividend Yield of Everest Organics Ltd is 0.00 %.
What is the ROCE of Everest Organics Ltd?
The ROCE of Everest Organics Ltd is 1.76 %.
What is the ROE of Everest Organics Ltd?
The ROE of Everest Organics Ltd is 2.23 %.
What is the Face Value of Everest Organics Ltd?
The Face Value of Everest Organics Ltd is 10.0.